Natalie S. Ryan

Natalie S. Ryan

UCL Queen Square Institute Of Neurology
London, ENG, United Kingdom

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 89 publications

Biomarker Variability Limits Individualized Amyloid Time Estimation in Alzheimer Disease.

Biomarker Variability Limits Individualized Amyloid Time Estimation in Alzheimer Disease.

Journal: bioRxiv : the preprint server for biology
Published: July 29, 2026

Biomarker Variability Limits Individualized Amyloid Time Estimation in Alzheimer Disease.

Biomarker Variability Limits Individualized Amyloid Time Estimation in Alzheimer Disease.

Journal: bioRxiv : the preprint server for biology
Published: July 29, 2026

Exome analysis of 22,319 individuals links extremely rare copy-number variants and 22q11.21 dosage to Alzheimer risk.

Exome analysis of 22,319 individuals links extremely rare copy-number variants and 22q11.21 dosage to Alzheimer risk.

Journal: American journal of human genetics
Published: April 20, 2026

Presymptomatic plasma biomarkers in autosomal dominant Alzheimer's disease: sequence and timing.

Presymptomatic plasma biomarkers in autosomal dominant Alzheimer's disease: sequence and timing.

Journal: medRxiv : the preprint server for health sciences
Published: April 10, 2026

Effect of Cognitive Reserve on Age at Symptom Onset and Cognitive Decline in Individuals With Dominantly Inherited Alzheimer Disease.

Effect of Cognitive Reserve on Age at Symptom Onset and Cognitive Decline in Individuals With Dominantly Inherited Alzheimer Disease.

Journal: Neurology
Published: April 08, 2026

Presymptomatic plasma biomarkers in autosomal dominant Alzheimer's disease: sequence and timing.

Presymptomatic plasma biomarkers in autosomal dominant Alzheimer's disease: sequence and timing.

Journal: Journal of neurology, neurosurgery, and psychiatry
Published: March 30, 2026

Identification of genetic modifiers of autosomal dominant Alzheimer's disease: a genome-wide association study.

Identification of genetic modifiers of autosomal dominant Alzheimer's disease: a genome-wide association study.

Journal: The Lancet. Neurology
Published: February 23, 2026

Use of anti-amyloid-β monoclonal antibodies in persons with Down syndrome Alzheimer's disease.

Use of anti-amyloid-β monoclonal antibodies in persons with Down syndrome Alzheimer's disease.

Journal: Alzheimer's & dementia : the journal of the Alzheimer's Association
Published: November 11, 2025

Visual modulation of vestibular-evoked balance response disturbed by posterior cortical atrophy.

Visual modulation of vestibular-evoked balance response disturbed by posterior cortical atrophy.

Journal: The Journal of physiology
Published: November 10, 2025

Alzheimer's disease in Down syndrome: progress and promise.

Alzheimer's disease in Down syndrome: progress and promise.

Journal: The Lancet. Neurology
Published: July 25, 2025

Comparison of amyloid chronicity and EYO in autosomal dominant Alzheimer's disease.

Comparison of amyloid chronicity and EYO in autosomal dominant Alzheimer's disease.

Journal: Alzheimer's & dementia : the journal of the Alzheimer's Association
Published: June 17, 2025

The relationship between amyloid-β peptide spectrum and the spastic paraparesis phenotype in autosomal dominant Alzheimer's disease.

The relationship between amyloid-β peptide spectrum and the spastic paraparesis phenotype in autosomal dominant Alzheimer's disease.

Journal: Alzheimer's research & therapy
Published: March 31, 2025
Showing 1-12 of 89

Last Updated: 09/26/2026